111 related articles for article (PubMed ID: 6798249)
1. Combination therapy using 9,3"-di-O-acetyl-midecamycin with beta-lactam antibiotics against Pseudomonas aeruginosa infection.
Mashimo K; Homma JY; Iki Y; Inatomi K; Kasai T; Kunii O; Shimada K; Tanimoto H; Takigami T; Nishimura Y
Jpn J Exp Med; 1981 Oct; 51(5):271-85. PubMed ID: 6798249
[TBL] [Abstract][Full Text] [Related]
2. Combined action of semisynthetic penicillin and macrolide antibiotic on Pseudomonas aeruginosa in vitro and in vivo.
Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1979 Oct; 49(5):331-6. PubMed ID: 119075
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
4. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
Nichols L; Maki DG
Chemioterapia; 1985 Feb; 4(1):102-9. PubMed ID: 3986938
[TBL] [Abstract][Full Text] [Related]
5. [Use of miocamycin in respiratory tract diseases].
Rimoldi R; Fioretti M; Bandera M
Ann Ist Super Sanita; 1987; 23(4):891-4. PubMed ID: 3502553
[No Abstract] [Full Text] [Related]
6. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003).
Shigemura K; Arakawa S; Sakai Y; Kinoshita S; Tanaka K; Fujisawa M
Int J Urol; 2006 May; 13(5):538-42. PubMed ID: 16771722
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
8. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
Hayes D; Kanga JF; Anstead MI; Kuhn RJ
Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117
[TBL] [Abstract][Full Text] [Related]
9. Improving the adequacy of empirical beta-lactam therapy for Pseudomonas aeruginosa ventilator-associated pneumonia.
Depuydt P; Blot S; Benoit D; Decruyenaere J
Int J Antimicrob Agents; 2008 May; 31(5):489-90. PubMed ID: 18313271
[No Abstract] [Full Text] [Related]
10. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
[TBL] [Abstract][Full Text] [Related]
11. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
Rossolini GM; Mantengoli E
Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
[TBL] [Abstract][Full Text] [Related]
13. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals.
Zavascki AP; Barth AL; Gaspareto PB; Gonçalves AL; Moro AL; Fernandes JF; Goldani LZ
J Antimicrob Chemother; 2006 Oct; 58(4):882-5. PubMed ID: 16895936
[TBL] [Abstract][Full Text] [Related]
15. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
[TBL] [Abstract][Full Text] [Related]
16. Community-acquired Pseudomonas aeruginosa urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and treatment.
Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G
Infection; 2008 Oct; 36(5):421-6. PubMed ID: 18795227
[TBL] [Abstract][Full Text] [Related]
17. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.
Ho SA; Lee TW; Denton M; Conway SP; Brownlee KG
J Cyst Fibros; 2009 Jan; 8(1):43-6. PubMed ID: 18829398
[TBL] [Abstract][Full Text] [Related]
18. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
[TBL] [Abstract][Full Text] [Related]
19. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
Rahal JJ
Clin Infect Dis; 2006 Sep; 43 Suppl 2():S95-9. PubMed ID: 16894522
[TBL] [Abstract][Full Text] [Related]
20. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
Obritsch MD; Fish DN; MacLaren R; Jung R
Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
